Expanding the Use of an Immunotherapeutic to Colorectal Cancer
The FDA expanded the use of the immunotherapy nivolumab to include the treatment of certain patients with colorectal cancer.
Progress Against Cancer
The FDA expanded the use of the immunotherapy nivolumab to include the treatment of certain patients with colorectal cancer.
The FDA approved the first of a new class of immunotherapy known as CAR T-cell therapy for treating patients with acute lymphoblastic leukemia.
Study: Women with periodontal disease had higher risk of several cancer types, including breast cancer, esophageal cancer, and oral cancer.
A study found that cancer patients were more likely to be approved for clinical trials after the passage of the Affordable Care Act.
The FDA approved a molecularly targeted therapeutic for treating certain patients with HER2-positive breast cancer.
A new study found disparities in secondhand smoke exposure among nonsmoking adult cancer survivors. Those who had a smoking-related cancer and those who were socioeconomically disadvantaged had higher rates of exposure. The adverse consequences...
The FDA’s recent announcement means the immune checkpoint inhibitor pembrolizumab is now approved for five forms of cancer. The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab (Keytruda) for the treatment of certain...
The FDA approved the first cancer treatment for use based on the tumor having certain biomarkers and not where in the body the tumor originated.
The FDA approved an immune checkpoint inhibitor – a type of immunotherapy – to treat certain patients with bladder cancer.
The FDA has approved a new immune checkpoint inhibitor, durvalumab, for the treatment of certain bladder cancer patients.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More